Clinical Trial Update: Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ixabepilone in patients with recurrent or persistent uterine cancer has completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Carcinosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• Ixabepilone (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2017-01-23